IRCT20230905059361N1 IRCT 2023-10-03 Shahre-kord University of Medical Sciences Fampridine effect on Parkinson disease symptoms Evaluation of the effects of Fampridine (4-aminopyridine) on motor and non-motor symptoms of Parkinson: A randomized double blind trial 2023-09-22 anticipated 62 Complete https://irct.ir/trial/72508 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to start the clinical trial study, with the coordination of the supervisor, 62 patients will be randomly selected from among the patients who meet the entry criteria referring to the neurology clinic, according to the sample size if they meet the entry criteria. Then, people will be assigned to two equal intervention and control groups using the random block allocation method with blocks of 2, 4, and 6, and the order of assigning each person to each group is placed in a sealed envelope based on blocks with a random number. The same number of people are assigned to each of the studied groups, Blinding description: The participants do not know whether they are part of the intervention or control group and do not know whether they are taking medicine or placebo. Medicines and placebos are given to patients by clinical caregivers, and the researcher does not know who received medicine or placebos. 3 Parkinson disease. Intervention 1: Intervention group: One group will receive fampridine tablets (Cinagen Pharmaceutical Company) as the intervention group. The new drug will be part of their treatment regimen along with the routine treatment regimen and the new treatment regimen will continue as before. The intervention group will receive fampridine tablets with a dose of 10 mg twice a day (Cinagen Pharmaceutical Company) for one month, which is currently considered as the duration of the study. Intervention 2: Control group: A group with the same size as the intervention group that receives placebo in the same amount and duration as the intervention group. Yes - There is a plan to make this available What will be shared: The data of the study before and after the intervention are collected and published to check the results of the intervention When: The access period starts about 6 months after the publication of the study results To whom: Scientific institutions, students, professors, pharmacists, manufacturing companies Conditions: Doctors to use the results of the study in better treatment of the disease Pharmacists for more effort in improving the quality of this drug Professors and students to know more about the effect of this medicine Manufacturing companies to invest in more and better drug production Where to obtain: Mohammad Shams Hafshejani Contact: +989136763428 Email: Mohammadsh3428@gmail.com How to obtain: After contacting the person with the required information and after confirming the validity of the applicant, the method of obtaining the required information will be announced to the applicant within a few days. Comments: